SEOM clinical guideline of diagnosis and management of low-grade glioma (2017)

AbstractDiffuse infiltrating low-grade gliomas include oligodendrogliomas and astrocytomas, and account for about 5% of all primary brain tumors. Treatment strategies for these low-grade gliomas in adults have recently changed. The 2016 World Health Organization (WHO) classification has updated the definition of these tumors to include their molecular characterization, including the presence of isocitrate dehydrogenase (IDH) mutation and 1p/19p codeletion. In this new classification, the histologic subtype of grade II-mixed oligoastrocytoma has also been eliminated. The precise optimal management of patients with low-grade glioma after resection remains to be determined. The risk–benefit ratio of adjuvant treatment must be weighed for each individual.

[1]  Desmond Curran,et al.  Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised Phase III trial on dose response (EORTC trial 22844) , 1998 .

[2]  S. Baum,et al.  The Effects of Aspirin on Gastric Prostaglandins , 1994, Annals of Internal Medicine.

[3]  D. Orringer,et al.  Advances in the Surgical Management of Low-Grade Glioma. , 2015, Seminars in radiation oncology.

[4]  Michael R. Johnson,et al.  Integrated systems‐genetic analyses reveal a network target for delaying glioma progression , 2019, Annals of clinical and translational neurology.

[5]  Yukui Wei,et al.  A Mistaken Diagnosis of Secondary Glioblastoma as Parasitosis , 2019, Front. Neurol..

[6]  Brigitta G. Baumert,et al.  Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma , 2016, The Lancet. Oncology.

[7]  L. Bello,et al.  Low-grade glioma management: a contemporary surgical approach , 2014, Current opinion in oncology.

[8]  B. Scheithauer,et al.  Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Steven N. Kalkanis,et al.  The role of radiotherapy in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline. , 2015 .

[10]  A. Karim,et al.  A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. , 1996, International journal of radiation oncology, biology, physics.

[11]  A. Škoch,et al.  Potential of MR spectroscopy for assessment of glioma grading , 2013, Clinical Neurology and Neurosurgery.

[12]  A. Karim,et al.  Prognostic factors for survival in adult patients with cerebral low-grade glioma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  G. Hutter,et al.  IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival. , 2013, Neuro-oncology.

[14]  B. Scheithauer,et al.  Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  E. Shaw,et al.  Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. , 2008, Journal of neurosurgery.

[16]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[17]  Nader Pouratian,et al.  Management of Low-Grade Glioma , 2010, Current neurology and neuroscience reports.

[18]  K. Sepkowitz,et al.  Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. , 2001, Hematology. American Society of Hematology. Education Program.

[19]  Winand N M Dinjens,et al.  Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Philippe Cornu,et al.  Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. , 2002, International journal of radiation oncology, biology, physics.

[21]  C. Dykewicz.  Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  M. Piérart,et al.  Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial , 2005, The Lancet.

[23]  E. Shaw,et al.  Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[25]  Susan M. Chang,et al.  Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. , 2008, Journal of neurosurgery.

[26]  Walter J. Curran,et al.  Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. , 2016, The New England journal of medicine.

[27]  A. Karim,et al.  Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group. , 1998, European journal of cancer.

[28]  Laurent Capelle,et al.  Dynamic history of low‐grade gliomas before and after temozolomide treatment , 2007, Annals of neurology.

[29]  Lu Gao,et al.  Development and validation of a nomogram with an autophagy-related gene signature for predicting survival in patients with glioblastoma , 2019, Aging.

[30]  Benjamin M. Ellingson,et al.  Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials , 2017, Neurotherapeutics.

[31]  Susan M. Chang,et al.  Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide , 2016, Neuro-oncology.

[32]  S. Coons,et al.  Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424. , 2015, International journal of radiation oncology, biology, physics.

[33]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[34]  J. Olson,et al.  The role of surgery in the management of patients with diffuse low grade glioma , 2015, Journal of Neuro-Oncology.

[35]  K. Aldape,et al.  IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas , 2015, Acta Neuropathologica.

[36]  K. Aldape,et al.  Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial. , 2016 .

[37]  David T. W. Jones,et al.  ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma , 2014, Acta Neuropathologica.